IDH mutations in glioma and acute myeloid leukemia (Q37778541)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 05 August 2010

Language	Label	Description	Also known as
English	IDH mutations in glioma and acute myeloid leukemia	scientific article published on 05 August 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1 reference

Europe PubMed Central

IDH mutations in glioma and acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

1 reference

based on heuristic

inferred from title

author name string

Lenny Dang

1

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Shengfang Jin

2

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Shinsan M. Su

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692206

18 June 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20692206

18 June 2024

publication date

5 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S1471491410000985?httpAccept=text/xml

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

https://api.elsevier.com/content/article/PII:S1471491410000985?httpAccept=text/plain

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Trends in Molecular Medicine

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

387-397

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

The consensus coding sequences of human breast and colorectal cancers

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.1133427

The Hallmarks of Cancer

1

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Understanding the Warburg effect: the metabolic requirements of cell proliferation

2

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Cancer as a metabolic disease

3

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Mitochondrial metabolism and cancer

4

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation.

5

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

HIF and fumarate hydratase in renal cancer

6

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Epidemiology of brain tumors.

7

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Epidemiology and etiology of gliomas

8

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Genetic pathways to primary and secondary glioblastoma

9

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Genetic pathways to glioblastoma: a population-based study

10

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

11

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Genetic alterations and signaling pathways in the evolution of gliomas

12

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter

13

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Lessons learned in the development of targeted therapy for malignant gliomas.

14

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

15

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

An integrated genomic analysis of human glioblastoma multiforme

16

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

17

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Analysis of the IDH1 codon 132 mutation in brain tumors

18

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Mutant metabolic enzymes are at the origin of gliomas

19

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

p53, the cellular gatekeeper for growth and division

20

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome

21

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

22

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 and IDH2 mutations in gliomas

23

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

24

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

25

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

26

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

27

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Molecular signatures classify astrocytic gliomas by IDH1 mutation status.

28

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

29

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system

30

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Recurring mutations found by sequencing an acute myeloid leukemia genome

31

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

32

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

33

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study

34

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

35

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

36

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

37

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

38

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms

39

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q).

40

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.

41

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

42

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence

43

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Identification and functional characterization of a novel, tissue-specific NAD(+)-dependent isocitrate dehydrogenase beta subunit isoform

44

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Substrate and functional diversity of lysine acetylation revealed by a proteomics survey

45

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

47

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

48

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity

49

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Critical Role of Lys212 and Tyr140 in Porcine NADP-dependent Isocitrate Dehydrogenase

50

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

51

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver. Evidence from isotopomer analysis of citric acid cycle intermediates

52

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

53

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer

54

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Metabolic enzymes as oncogenes or tumor suppressors

55

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Mutation and cancer: statistical study of retinoblastoma

56

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing

57

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition?

58

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect

59

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria

60

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Identification of the d-enantiomer of 2-hydroxyglutaric acid in glutaric aciduria type II

61

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes

62

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

63

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Targeting HIF-1 for cancer therapy

64

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase

65

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Structural insights into histone demethylation by JMJD2 family members.

66

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

67

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria

69

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats

70

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer

71

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

The pentose phosphate cycle is regulated by NADPHNADP ratio in rat liver

72

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers

73

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent

74

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Gossypol: prototype of inhibitors targeted to dinucleotide folds

76

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox

77

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

L-2 hydroxyglutaric aciduria: proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging findings

78

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma

79

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

80

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

81

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.

82

1 reference

10.1016/J.MOLMED.2010.07.002

https://api.crossref.org/works/10.1016/J.MOLMED.2010.07.002

18 June 2024

Identifiers

10.1016/J.MOLMED.2010.07.002

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37778541&oldid=2182781415"